Combo Disappoints in Metastatic Prostate Cancer ...Middle East

Medscape - News
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer, according to researchers. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Combo Disappoints in Metastatic Prostate Cancer )

Apple Storegoogle play

Also on site :

Most viewed in News


Latest News